MedTrace Logo

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

NCT07122687 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2025-09-30

No results posted yet for this study

Summary

This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.

Conditions

  • Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed

500 mg/m2 D1 IV Q3W

DRUG

Cisplatin

75 mg/m2 D1 IV Q3W

DRUG

IBI363

1.5 mg/kg D1 IV Q3W

DRUG

Carboplatin

AUC 5 mg/ml/min D1 IV Q3W

DRUG

Keytruda

200mg D1 IV Q3W

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-26
Primary Completion
2026-11-30
Completion
2030-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07122687 on ClinicalTrials.gov